Cancers thoraciques et pulmonaires - études en cours

Contact : Vanessa Erculisse

  • ADRIATIC - Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT)
Sponsor : AstraZeneca
Principal investigateur : Th. Pieters

 

  • BFAST - A phase II/III ,multicenter study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring actionable somatic mutations detected in blood (B-Fast: Blood-first assay screening trial) 
Sponsor : Roche
Principal investigateur : Ph. Collard